Cristina F. Diestel
Rio de Janeiro State University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Cristina F. Diestel.
Acta Cirurgica Brasileira | 2007
Fernanda Correia Simões; Ruy Garcia Marques; Cristina F. Diestel; Carlos Eduardo R. Caetano; Ana Paula Gonçalves Dinis; Nara Limeira Horst; José Firmino Nogueira Neto; Margareth Crisóstomo Portela
PURPOSE To evaluate the alterations on plasmatic lipids levels among rats submitted to total splenectomy isolated or combined with splenic autotransplant receiving standard chow during the postoperative period. METHODS Thirty Wistar rats were divided into three groups: control (C)-- sham-operated, total splenectomy--isolated (TS) or combined with splenic autotransplantation (SA). Since the postoperative period, all animals received standard rat chow manipulated in accordance to the American Institute of Nutrition Rodents Diets (1993). The plasmatic levels of total cholesterol (TC), triglycerides (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), very-low-density lipoprotein (VLDL), and glucose (GLUC) were analyzed before the surgical procedure and after 6 and 12 weeks. RESULTS All the animals presented significant increase of TG and VLDL levels. In relation to the other parameters there was no difference among the weeks 0 and 12 in the animals of group C. In TS group significant increase was observed in TC and GLUC levels during the experiment. In SA group TC, HDL, and GLUC levels remained unaffected while HDL levels increased. CONCLUSION Our findings suggest that isolated total splenectomy alters lipids metabolism in rats fed with standard chow and splenic autotransplantation is effective in restoring its control.
Acta Cirurgica Brasileira | 2005
Cristina F. Diestel; Francisco Lopes-Paulo; Ruy Garcia Marques; Nara Limeira Horst; Carlos Eduardo R. Caetano
ABSTRACT – Purpose: To evaluate the structural alterations of the irradiated colonic wall in rats, verifying if L-glutaminesupplementation is able to prevent them. Methods: We used 30 male adult Wistar rats, divided into three groups: I – control, II –irradiated, and III – irradiated with L-glutamine supplementation during the 14 days of the study. Control group was maintained inlaboratory standard conditions while groups II and three were submitted to abdominal radiation with an only dose of 1000 cGy in the8 th day of experimentation. All the animals were submitted to laparotomy in the 15 th day for resection of the colonic segment forstereological analysis. Results: Group II presented total volume of colonic wall significantly smaller than control group withoutaltering the partial volumes of each layer. Compared to groups II and III, group III exhibited maintenance of total volume of c olonicwall, nearing control group. Compared to control group, animals of group III exhibited maintenance of epithelial partial volumewithout altering significantly epithelial surface.
Current Therapeutic Research-clinical and Experimental | 2009
Nara Limeira Horst; Ruy Garcia Marques; Cristina F. Diestel; Bianca D. Matzke; Carlos Eduardo R. Caetano; Fernanda Correia Simões; Arnaldo F.B. Andrade; Wagner I. Lobão; Luiz Carlos Aguiar Vaz; Margareth Crisóstomo Portela; José Ueleres Braga; Paulo A. Melo
BACKGROUND Intestinal barrier disruption followed by bacterial translocation seems to play a role in secondary pancreatic infection in acute pancreatitis. The use of probiotics as a possible adjuvant strategy in the treatment of acute pancreatitis needs to be investigated. OBJECTIVE The aim of this study was to determine the effects of dietary supplementation with a prophylactically administered multispecies probiotic mixture on the markers of acute pancreatitis and on the occurrence of bacterial translocation. METHODS Thirty adult male Wistar rats were randomly assigned to 1 of 3 groups of 10 rats each: (1) the PS group, in which the rats were given probiotic supplementation prior to induction of acute pancreatitis; (2) the WP group, in which the rats underwent surgery to induce acute pancreatitis without prior probiotic supplementation; and (3) the control group, in which the rats underwent sham surgery. For 14 days before surgery, animals in the PS group received a single daily dose containing ~1.2 × 10(9) colony-forming units of a probiotic mixture administered intragastrically as a bolus. On day 15, the animals underwent surgery to induce acute pancreatitis (PS and WP groups) or simulated surgery (control group). Blood samples were collected to determine leukocyte count, amylase and lipase activities, and glucose and calcium concentrations immediately before and 6 and 12 hours after the beginning of the procedure. Samples of pancreas, spleen, liver, and mesenteric lymph nodes were harvested for microbiologic and histopathologic analysis after the last blood sample collection. The pathologist examining the histopathology was blinded to treatment assignment. RESULTS The mean leukocyte count was significantly increased in the PS group compared with the WP group (P = 0.018), whereas the serum amylase and lipase activities and the serum glucose and calcium concentrations were not significantly different between the 2 groups. Comparing the risk for tissue colonization in the PS group with that of the WP group, the odds ratio (OR) for pancreas was 2.91 (95% CI, 0.13-67.10); liver, 66.55 (95% CI, 1.89-2282.66); spleen, 88.58 (95% CI, 3.04-2583.08); and mesenteric lymph nodes, 1.23 (95% CI, 0.06-25.48). When the risks for histopathologic changes were compared between the 2 groups, the OR for acinar necrosis was 1.73 (95% CI, 0.21-12.17); steatonecrosis, 12.08 (95% CI, 1.26-115.54); hemorrhage, 1.38 (95% CI, 0.21-9.53); and leukocyte infiltration, 5.91 (95% CI, 0.64-54.89). CONCLUSION Probiotic supplementation before the induction of acute pancreatitis was associated with a greater degree of bacterial translocation and pancreatic tissue damage in this animal model.
Archive | 2017
Cristina F. Diestel; Nara Limeira Horst; Alessandra da Rocha Pinheiro Mulder; Ruy Garcia Marques
Cancer is a multifactorial chronic disease caused by disorganized cell growth and is one of the most important causes of death in the world. Ionizing radiation is an important treatment for a number of malignancies, as surgery and chemotherapy. Radiotherapy is commonly administered to the abdomen and pelvis of patients with gastrointestinal (GI), urological, and gynaecological malignant neoplasms (Stacey and Green. Ther Adv Chronic Dis 5:15–29, 2014).
Gastroenterology | 2015
Ricardo J. Fittipaldi-Fernandez; Bruno Sander; Manoel Galvao Neto; Jimi Scarparo; Sergio Barrichello; Cristina F. Diestel
INTRODUCTION: The global increase in obesity incidence results in an increase of type 2 diabetes mellitus (T2DM) incidence. Surgical treatment has proven to be effective, however it carries a high risk of complications. The duodenal-jejunal bypass liner (EndoBarrier®, GI Dynamics, DJBL) is an endoscopic implant that mimics the intestinal bypass portion of the Roux-en-Y Bystric bypass. It results in weight loss and improvements in glucose control in obese patients with T2DM. AIMS & METHODS: This is an interim report of an ongoing three years study. The aim of this prospective, controlled, multicentre study is to determine the effectiveness of DJBL and to identify clinical factors associated with a sub-optimal outcome of DJBL. RESULTS: Forty four subjects (24 with an implant, 20 controls) were included in the study. The groups were comparable with respect to age, gender, BMI (mean 37.7 vs. 38.1 kg/m2), T2DM duration (7.2 vs. 8.3 years), HbA1c level (8.8 % vs 8.1 %) and T2DM treatment. In the DJBL group, all devices were successfully implanted. Only three devices had to be explanted prior to the end of the 6 months study period (bleeding, dislocation and need for ERCP because of choledocholithiasis). The mean procedure time was 21.2 minutes for an implantation and 35.5 minutes for an explantation. At six months there was significantly greater weight loss (27% vs. 9%) and significantly improved HbA1c % (2.3 vs. 1.1) in the DJBL group. T2DMmedicinal treatment could be reduced in more device subjects than controls. There was no serious adverse event. Mild abdominal pain and nausea after implantation were experienced by 75% of patients during first 14 days after implantation, 40% of patients during the first month and 11% of patiens after one month. Lower initial BMI, distal position of the anchor and lower body height were identified as negative prognostic factors for pain. CONCLUSION: The DJBL is safe when implanted for 6 months, and results in significant weight loss and HbA1c reduction. This suggests that this novel device is a candidate for the primary therapy of morbid obesity and type 2 diabetes. Lower initial BMI, distal position of the anchor and lower body height could be negative prognostic factor for pain
Gastroenterology | 2015
Ricardo J. Fittipaldi-Fernandez; Cristina F. Diestel
INTRODUCTION: The global increase in obesity incidence results in an increase of type 2 diabetes mellitus (T2DM) incidence. Surgical treatment has proven to be effective, however it carries a high risk of complications. The duodenal-jejunal bypass liner (EndoBarrier®, GI Dynamics, DJBL) is an endoscopic implant that mimics the intestinal bypass portion of the Roux-en-Y Bystric bypass. It results in weight loss and improvements in glucose control in obese patients with T2DM. AIMS & METHODS: This is an interim report of an ongoing three years study. The aim of this prospective, controlled, multicentre study is to determine the effectiveness of DJBL and to identify clinical factors associated with a sub-optimal outcome of DJBL. RESULTS: Forty four subjects (24 with an implant, 20 controls) were included in the study. The groups were comparable with respect to age, gender, BMI (mean 37.7 vs. 38.1 kg/m2), T2DM duration (7.2 vs. 8.3 years), HbA1c level (8.8 % vs 8.1 %) and T2DM treatment. In the DJBL group, all devices were successfully implanted. Only three devices had to be explanted prior to the end of the 6 months study period (bleeding, dislocation and need for ERCP because of choledocholithiasis). The mean procedure time was 21.2 minutes for an implantation and 35.5 minutes for an explantation. At six months there was significantly greater weight loss (27% vs. 9%) and significantly improved HbA1c % (2.3 vs. 1.1) in the DJBL group. T2DMmedicinal treatment could be reduced in more device subjects than controls. There was no serious adverse event. Mild abdominal pain and nausea after implantation were experienced by 75% of patients during first 14 days after implantation, 40% of patients during the first month and 11% of patiens after one month. Lower initial BMI, distal position of the anchor and lower body height were identified as negative prognostic factors for pain. CONCLUSION: The DJBL is safe when implanted for 6 months, and results in significant weight loss and HbA1c reduction. This suggests that this novel device is a candidate for the primary therapy of morbid obesity and type 2 diabetes. Lower initial BMI, distal position of the anchor and lower body height could be negative prognostic factor for pain
International Journal of Colorectal Disease | 2007
Cristina F. Diestel; Ruy Garcia Marques; Francisco Lopes-Paulo; Daurita Darci de Paiva; Nara Limeira Horst; Carlos Eduardo R. Caetano; Margareth Crisóstomo Portela
International Journal of Colorectal Disease | 2011
Etiene de Aguiar Picanço; Francisco Lopes-Paulo; Ruy Garcia Marques; Cristina F. Diestel; Carlos Eduardo R. Caetano; Mônica Vieira Mano de Souza; Gabriela Mendes Moscoso; Helena M. F. Pazos
Lipids | 2009
Ana Paula Gonçalves Dinis; Ruy Garcia Marques; Fernanda Correia Simões; Cristina F. Diestel; Carlos Eduardo R. Caetano; Dióscuro José Ferreira Secchin; José Firmino Nogueira Neto; Margareth Crisóstomo Portela
Obesity Surgery | 2017
Ricardo J. Fittipaldi-Fernandez; Marcella R. Guedes; Manoel Galvao Neto; Márcia Regina Simas Torres Klein; Cristina F. Diestel